Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in Germany align with existing clinical trial data.

A 65-year-old man developed a serious skin cancer linked to a drug he was taking for a fungal infection after a bone marrow transplant.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.

This study found that in noise-exposed FVB/NJ mice and cell models, ivacaftor reduced oxidative stress and hearing damage by maintaining CFTR function and increasing Nrf2 expression, suggesting its potential for treating noise-induced hearing loss.

In this experimental study, researchers found that intravitreal injections of up to 100μg of topotecan in rabbits caused no systemic or ocular toxicity, while 200μg doses resulted in localized retinal changes and decreased electroretinography amplitudes near the injection site.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

This review summarizes evidence and adverse event management recommendations for Sacituzumab Govitecan in metastatic triple-negative breast cancer and hormone receptor-positive breast cancer, emphasizing favorable survival data from clinical trials.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

This study found that 3D imaging may serve as a promising tool for objectively evaluating facial vitiligo repigmentation after treatment with upadacitinib.

In a mouse model of chemotherapy-induced alopecia, this study found that enhancing ETV2 expression improved angiogenesis and hair regrowth following 5-fluorouracil treatment.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study found that betibeglogene autotemcel significantly improved transfusion independence in 89% of patients with transfusion-dependent beta-thalassemia, although the high cost and manufacturing challenges may limit widespread adoption.

This Phase 1 study reported that topical application of BPM31543 was safe and well-tolerated in patients receiving taxane-based chemotherapy, with some experiencing less than 50% hair loss, suggesting potential efficacy in reducing chemotherapy-induced alopecia, although no maximum tolerated dose was identified.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

In this study, hypoxic conditions were found to enhance stemness in hair follicle neural crest stem cells, while inhibiting the Hippo pathway significantly decreased their proliferation.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

This study evaluated the real-world safety of Tepotinib for treating NSCLC with METex14 skipping mutations, confirming known adverse events and identifying new signals like deafness and taste disorder, especially highlighting early monitoring.

This study found that combining topical minoxidil with phototherapy significantly improved pigmentation and reduced vitiligo severity compared to placebo, as measured by VASI scores over 12 weeks, though the sample size was small and follow-up short.

In this study, two male patients with androgenetic alopecia who had previously undergone hair transplants showed increased hair regrowth after receiving verteporfin injections, with a 63% mean increase in dense donor sites, 38% in thinning areas, but no growth in bald areas.

This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.

In this study, GV-350 treatment over three months improved iron status and reduced the impact of Telogen Effluvium on quality of life among 20 iron-deficient women, with no adverse events reported.

This report describes a case where a young woman developed Kerion Celsi, a fungal skin infection, potentially linked to the use of a tretinoin, minoxidil, and betamethasone valerate lotion.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This clinical study observed that in patients with advanced breast cancer and BRCA1/2 mutations, talazoparib provided significantly better progression-free survival, objective response, clinical benefit, and patient-reported outcomes compared to physician’s choice chemotherapy, despite common side effects like anemia and fatigue.

This study found that nobiletin-loaded vesicles effectively restored skin condition in a mouse model of skin cancer, suggesting they are a promising treatment delivery system.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.